ADIENNE is an integrated biopharmaceutical group of companies based in Lugano, Switzerland, with a proprietary portfolio of orphan-designated marketed medicinal product, clinical and preclinical product candidates focusing on critical conditions of high unmet medical needs.

ADIENNE aims to develop a range of product candidates for orphan diseases for which existing treatment options are limited, the patient population is small and the clinical needs for therapies is high.

ADIENNE AT WORLD AND EUROPEAN PHARMACOVILANCE CONGRESSES 2019 - We are pleased to announce that for a second consecutive year Dr. Marco Sardella, Chief Pharmacovigilance Officer and EU QPPV ADIENNE Pharma & Biotech, will chair the Advance Therapy/Orphan Drug Stream at the World Drug Safety Congress taking place in Amsterdam on Sep. 10-11, 2019 (Full agenda and detailed information on the congress are available at the following LINK) and  will be Chairman of the European Pharmacovigilance Congress taking place in Milan on Nov. 28-29, 2019 (Full agenda and detailed information on the congress are available at the following LINK).

ADIENNE is a landmark in the field of global pharmacovigilance. We warmly congratulate Dr. Sardella and look forward to this upcoming events.